Clopidogrel Dosing and Duration in Acute Coronary Syndromes and PCI

Loading Dose Recommendations

Give a 300–600 mg oral loading dose of clopidogrel as soon as possible when acute coronary syndrome (ACS) is suspected or confirmed. This rapid‑onset strategy is endorsed by the American Heart Association (AHA) and the American College of Cardiology (ACC). 1
A 600 mg loading dose provides faster and more complete platelet inhibition than a 300 mg dose, although both doses are acceptable. (ACC) 2
Administer the loading dose at least 2–6 hours before percutaneous coronary intervention (PCI) whenever feasible to ensure optimal platelet inhibition at the time of the procedure. (ACC) 3

For patients younger than 75 years receiving fibrinolytic therapy for STEMI, use a 300 mg clopidogrel loading dose. (AHA) 4
For patients aged ≥ 75 years, omit the loading dose because of an increased bleeding risk. (ACC) 2

Continue clopidogrel 75 mg once daily for at least 12 months after stent implantation (bare‑metal or drug‑eluting) unless the bleeding risk outweighs the benefit. (AHA/ACC) 1
In selected patients with drug‑eluting stents, therapy may be extended beyond 12–15 months. (AHA/ACC) 1

Bare‑metal stent (BMS): maintain therapy for a minimum of 1 month, ideally up to 12 months. (AHA/ACC) 1
Drug‑eluting stent (DES): maintain therapy for at least 12 months. (European Society of Cardiology, ESC) 5
After ACS without stent placement, continue clopidogrel for at least 12 months. (ESC) 5

Give a 600 mg loading dose at least 2 hours before elective PCI (or a 300 mg dose at least 6 hours before). (ACC) 2
If aspirin is contraindicated, administer 300–600 mg clopidogrel at least 6 hours before PCI. (ACC) 3

Discontinue clopidogrel 5–7 days before elective coronary artery bypass grafting (CABG) to reduce surgical bleeding. (AHA/ACC) 1

Dual antiplatelet therapy (clopidogrel + aspirin) raises major bleeding rates by approximately 1 % (from 2.7 % to 3.7 %) compared with aspirin alone. (ESC) 5
The modest increase in bleeding is offset by a ~20 % reduction in cardiovascular death, myocardial infarction, and stroke in ACS patients. (ESC) 5

Avoid concomitant use of strong CYP2C19 inhibitors (e.g., omeprazole, esomeprazole) because they diminish clopidogrel’s antiplatelet effect. (ACC) 2

A history of stroke or transient ischemic attack (TIA) contraindicates prasugrel but does not preclude clopidogrel use. (AHA/ACC) 1
Age ≥ 75 years or body weight < 60 kg increases bleeding risk with prasugrel, whereas clopidogrel remains acceptable. (ACC) 2

A 600 mg oral loading dose of clopidogrel provides faster and more complete platelet inhibition than a 300 mg dose and is endorsed by the European Society of Cardiology (ESC) guidelines for patients undergoing percutaneous coronary intervention (PCI). 6, 7
The 600 mg loading dose yields superior platelet inhibition within 4 hours and is associated with a reduction in major adverse cardiovascular events (MACE) compared with the 300 mg regimen. 8

For primary PCI in STEMI, administer at least a 300 mg loading dose—preferably 600 mg—as early as possible, ideally before or at the time of catheterisation. 6, 7
Patients who have been on clopidogrel 75 mg daily for ≥7 days and present with ACS or require urgent PCI should receive an additional 300–600 mg loading dose to achieve rapid platelet inhibition. 8

After ACS or stent implantation, continue clopidogrel 75 mg once daily for a minimum of 12 months unless the bleeding risk outweighs the antithrombotic benefit. 7
For drug‑eluting stents, a minimum of 12 months of clopidogrel therapy is recommended. 7

The CURRENT‑OASIS 7 trial demonstrated that a double‑dose clopidogrel strategy (600 mg loading followed by 150 mg daily for 6 days) increased major bleeding (2.5 % vs 2.0 %) without a significant overall benefit in the ACS population, although it reduced stent thrombosis in the PCI subgroup. 8

Co‑administration of enteric‑coated aspirin with a clopidogrel loading dose delays the antiplatelet effect; chewable or intravenous aspirin should be used instead. 6